Regulatory Reactivity in FDA’s Approval of Aduhelm
A controversial approval of an Alzheimer’s treatment reveals a core weakness in oversight of agency discretion.
Yaniv Heled
A controversial approval of an Alzheimer’s treatment reveals a core weakness in oversight of agency discretion.